LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Inicio・Lista de Acciones・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Cerrado

SectorSalud

225.42 -1.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

220.64

Máximo

228.98

Métricas clave
By Trading Economics
Ingresos	28M -33M
Ventas	32M 245M
Margen de beneficio	-13.56
Empleados	1,189
EBITDA	68M 15M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+26.13% upside

Dividendos
By Dow Jones
Próximas Ganancias	30 abr 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-288M 13B
Apertura anterior	226.97
Cierre anterior	225.42

Noticias sobre sentimiento de mercado

By Acuity

54%

46%

290 / 351 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

157.66 / 167.29 Soporte y Resistencia

Ascendis Pharma A-S ADR Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 feb 2026, 17:37 UTC

Adquisiciones, fusiones, absorciones

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

20 feb 2026, 16:18 UTC

Principales Movimientos del Mercado

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

20 feb 2026, 23:12 UTC

Adquisiciones, fusiones, absorciones

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

20 feb 2026, 22:12 UTC

Ganancias

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

20 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

20 feb 2026, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

20 feb 2026, 21:23 UTC

Ganancias

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

20 feb 2026, 21:20 UTC

Charlas de Mercado

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

20 feb 2026, 21:01 UTC

Adquisiciones, fusiones, absorciones

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

20 feb 2026, 20:38 UTC

Charlas de Mercado

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

20 feb 2026, 20:17 UTC

Charlas de Mercado

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

20 feb 2026, 20:11 UTC

Charlas de Mercado

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

20 feb 2026, 19:59 UTC

Charlas de Mercado

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

20 feb 2026, 19:58 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

20 feb 2026, 19:49 UTC

Charlas de Mercado

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

20 feb 2026, 19:09 UTC

Charlas de Mercado

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

20 feb 2026, 19:00 UTC

Charlas de Mercado

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

20 feb 2026, 18:28 UTC

Charlas de Mercado

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

20 feb 2026, 18:20 UTC

Charlas de Mercado

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

20 feb 2026, 18:05 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 18:04 UTC

Charlas de Mercado

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

20 feb 2026, 17:38 UTC

Charlas de Mercado

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

20 feb 2026, 17:24 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 17:24 UTC

Charlas de Mercado

Correction to Treasury Yields Fall Market Talk

20 feb 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

20 feb 2026, 16:53 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

20 feb 2026, 16:53 UTC

Charlas de Mercado

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

20 feb 2026, 16:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

20 feb 2026, 16:45 UTC

Charlas de Mercado

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

20 feb 2026, 16:40 UTC

Charlas de Mercado

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Comparación entre iguales

Cambio de precio

Ascendis Pharma A-S ADR Esperado

Precio Objetivo

By TipRanks

26.13% repunte

Estimación a 12 meses

Media 290.36 USD 26.13%

Máximo 342 USD

Mínimo 250 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Ascendis Pharma A-S ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

157.66 / 167.29Soporte y Resistencia

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

290 / 351 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.